# Insmed (INSM) — Overview

INSM · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/insm

## Price

Last close $99.21 on Oct 15, 2026. 52-week range $91.88 – $211.41.

## Company profile

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $1.1B |
| Revenue (quarter) | $425.5M |
| Revenue growth (year over year) | 296.11% |
| Gross profit (trailing twelve months) | $949.4M |
| Gross margin | 83.46% |
| Net income (trailing twelve months) | −$875.3M |
| Net income (quarter) | −$13.2M |
| Net income growth (year over year) | 95.88% |
| Net margin | -76.94% |
| Return on equity | -87.22% |
| EPS (trailing twelve months) | −$4.12 |
| Book value per share | $3.47 |
| P/E (trailing twelve months) | — |
| Price to book | 28.6 |
| Debt to assets | 63.97% |
| Payout ratio | 0.00% |
| Dividend yield | 0.00% |

## Frequently Asked Questions

### Is Insmed (INSM) profitable?

No. Insmed reported a net loss of $875.3M over the trailing twelve months.

### How much revenue does Insmed (INSM) make?

Insmed generated $1.1B in revenue over the trailing twelve months, up 296.11% year over year.

### How do I buy stock in Insmed (INSM)?

INSM trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).